Ovarian cancer physical examination

Jump to navigation Jump to search

Ovarian cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classifications

Pathophysiology

Causes of Ovarian cancer

Differentiating Ovarian cancer from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Staging

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ovarian cancer physical examination On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ovarian cancer physical examination

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ovarian cancer physical examination

CDC on Ovarian cancer physical examination

Ovarian cancer physical examination in the news

Blogs on Ovarian cancer physical examination

Directions to Hospitals Treating Ovarian cancer

Risk calculators and risk factors for Ovarian cancer physical examination

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Monalisa Dmello, M.B,B.S., M.D. [2]; Associate Editor(s)-in-Chief: Huda A. Karman, M.D.

Overview

Ovarian cancer physical exam findings varies from patient to another but usually the symptoms and signs are nonspecific and the cancer is discovered in its late stages. The findings in the physical exam can be palpable adnexal mass, ascites, pleural effusion, bowel obstruction.

Physical exam

References

  1. White RH, Chew HK, Zhou H, Parikh-Patel A, Harris D, Harvey D; et al. (2005). "Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults". Arch Intern Med. 165 (15): 1782–7. doi:10.1001/archinte.165.15.1782. PMID 16087828.
  2. Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000). "Prognosis of cancers associated with venous thromboembolism". N Engl J Med. 343 (25): 1846–50. doi:10.1056/NEJM200012213432504. PMID 11117976.
  3. Friedrich M, Villena-Heinsen C, Schweizer J, Holländer M, Stieber M, Schmidt W (1998). "Primary tubal carcinoma: a retrospective analysis of four cases with a literature review". Eur J Gynaecol Oncol. 19 (2): 138–43. PMID 9611053.
  4. Hippisley-Cox J, Coupland C (2011). "Identifying women with suspected ovarian cancer in primary care: derivation and validation of algorithm". BMJ. 344: d8009. doi:10.1136/bmj.d8009. PMC 3251328. PMID 22217630.
  5. Hamilton W, Peters TJ, Bankhead C, Sharp D (2009). "Risk of ovarian cancer in women with symptoms in primary care: population based case-control study". BMJ. 339: b2998. doi:10.1136/bmj.b2998. PMC 2731836. PMID 19706933.
  6. SINHA AC (1959). "Hydrops tubae profluens as a presenting symptom in primary carcinoma of the fallopian tube: report of two cases and review of literature". Br Med J. 2 (5158): 996–1001. doi:10.1136/bmj.2.5158.996. PMC 1990718. PMID 14447118.
  7. Ou YC, Huang HY, Huang CC, Changchien CC, Tseng CW, Lin H (2011). "Primary fallopian tube carcinoma: clinicopathological analysis of 12 cases". Taiwan J Obstet Gynecol. 50 (2): 141–4. doi:10.1016/j.tjog.2011.01.031. PMID 21791297.

Template:WH

Template:WS